Sai Life Sciences

    SAILIFE
    Pharma
    ₹1,788.10
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹37,992 Cr

    P/E
    101.71
    Day range
    ₹1,750.40 – ₹1,819.20
    52-week range
    ₹783.85 – ₹1,954.80
    Volume
    11.87 L
    Open
    ₹1,751.50
    Prev close
    ₹1,751.50

    Latest results · Q2 FY27(consolidated)Revenue ₹659 Cr+22.5%Profit ₹98 Cr+17.3%Margin 14.9%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 62 / 100

    Factor percentiles

    Value16
    Quality63
    Momentum94
    Low volatility73

    Derived metrics

    Earn. yield
    1.0%
    Graham no.
    ₹226.04
    vs Graham
    -87.4%
    ROE ÷ P/B
    1.1%
    12-1 mom.
    +53.2%
    Return / vol
    2.72
    Magic Formula
    #474
    FCF yield
    -0.2%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Sai Life SciencesSAILIFE₹37,992 Cr101.7114.1715.1%20.0%28.0%0.23+22.7%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 49m ago

    Headlines about Sai Life Sciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    100.0
    Price / Book
    14.08
    ROE (FY26)
    15.1%
    ROCE (latest year)
    20%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹1,630.61
    Price above
    50-day
    ₹1,577.71
    Price above
    200-day
    ₹1,248.37
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +21.7%
    Profit 3Y CAGR
    +226.8%
    Revenue YoY (Sep 2026)
    +22.7%
    Profit YoY (Sep 2026)
    +16.7%
    Operating margin
    28.0%
    Net margin
    14.9%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -200 Cr0 Cr200 Cr400 Cr600 Cr800 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY20FY21FY22FY23FY24FY25FY260%5%10%15%20%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x1x2x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales384439280396440580496537556602554659
    Expenses287315254293320422375392369426406472
    Operating Profit9612526102120158121146188177148186
    OPM %25%28%9%26%27%27%24%27%34%29%27%28%
    Other Income113810910101501644
    Interest232121212311129108811
    Depreciation313131363437384044454648
    Profit before tax5376-1855721198111213413998131
    Tax %25%26%-25%25%25%26%25%25%25%25%25%25%
    Net Profit4056-1442548860841001047398
    EPS in Rs————₹2.59₹4.24₹2.90₹4.00₹4.75₹4.92₹3.45₹4.63

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days62

    -37 days since Mar 2021

    Inventory Days97

    -30 days since Mar 2021

    Days Payable182

    -48 days since Mar 2021

    Cash Conversion Cycle-24

    -20 days since Mar 2021

    Working Capital Days70

    +8 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries [1]

    Strengths

    • Company has delivered good profit growth of 42.2% CAGR over last 5 years

    Risks

    • Stock is trading at 14.2 times its book value
    • Though the company is reporting repeated profits, it is not paying out dividend
    • Company has a low return on equity of 12.7% over last 3 years.
    • Working capital days have increased from 49.2 days to 69.8 days

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +24%
    3 Years
    +22%
    TTM
    +16%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +42%
    3 Years
    +227%
    TTM
    +33%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    —
    1 Year
    +105%

    Return on Equity

    10 Years
    —
    5 Years
    +9%
    3 Years
    +13%
    Last Year
    +15%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter34.70%34.61%34.53%34.50%-0.03 pp
    FII21.41%21.17%19.65%19.91%+0.26 pp
    DII31.41%31.54%32.71%32.32%-0.39 pp
    Public12.49%12.69%13.11%13.25%+0.14 pp

    Filed with NSE for Sept 2026: promoters 34.50%, public 65.50%

    Analysts & fund holdings

    88%
    88% recommend buy
    8 analysts cover the stock
    Valuation vs Biotechnology
    P/E101.7 vs 45.1
    Sector P/B6.03

    Who holds the shares, quarter by quarter

    Mutual funds 29.56% (+0.09 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters34.5%
    • Foreign institutions19.9%
    • Mutual funds29.6%
    • Insurance2.6%
    • Other domestic institutions0.1%
    • Retail5.0%
    • Others8.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Nippon India Small Cap Fund2.75%1.33%+0.24 pp
    Invesco India Large & Mid Cap Fund1.79%5.36%+0.57 pp
    Nippon India Multi Cap Fund1.75%1.21%+0.37 pp
    Invesco India Midcap Fund1.58%3.71%+0.65 pp
    Axis Small Cap Fund1.55%1.97%+0.32 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    35.6%
    Downside volatility
    31.9%
    Worst 5% of days
    3.4%
    Average of that tail
    4.6%
    Max drawdown (1Y)
    18.6%
    Below its peak
    7.3%

    Against the market

    Beta vs Nifty 50
    0.80
    Correlation
    0.31
    Relative strength (3M)
    +22.4%
    ATR (14)
    4.6%

    Return

    Return 1M
    +28.7%
    Return 3M
    +26.2%
    Return 6M
    +60.7%
    Return 1Y
    +97.1%
    vs 200-day average
    +43.2%

    Momentum

    RSI (14)
    62.2
    MACD histogram
    18.72
    Stochastic %K
    65.4
    ADX (14)
    35.1
    +DI / −DI
    28.6 / 15.7
    Money flow index
    86.4

    Participation

    Delivery (20d avg)
    42.8%
    vs its 60-day baseline
    -6.6 pts
    Volume vs 20-day
    -0.2σ
    Close vs day's VWAP
    -0.7%
    52-week position
    88 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.

    Free cash flow
    -₹84 Cr
    FCF yield
    -0.2%
    Cash conversion
    1.46
    Accruals ratio
    -0.044
    Net debt
    ₹589 Cr
    Net debt / equity
    0.22
    EV / sales
    16.27
    Capex intensity
    27.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    No dividends, splits or bonuses recorded for this company yet.

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended 30th September 2026.

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Unaudited Financial Results Of Q-2 (FY 2026-27)

    Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve unaudited financial results ....

    Insider Trading / SAST
    Closure of Trading Window

    Closure of Trading Window relating to Unaudited Financial Result for the Second Quarter and Half Year Ending on 30th September 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of 24,000 Equity Shares having Face Value of Rs. 1/- as per Company's ESOP Plan

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting Results and Scrutinizer's Report of 27th Annual General Meeting (AGM) of the Company

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of 27th Annual General Meeting (AGM) of the Company

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Investors Conference - 18th September 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Investors Conference - 14th September 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of 80,600 Equity shares having Face Value ?1/- each as per Company's ESOP Plans

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication relating to 27th AGM (Post-dispatch Advt.)

    Company Update
    Weblink Letter To Shareholders - As Per Regulation 36(1)(B) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Please refer the attachment

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    Business Responsibility and Sustainability Report (BRSR) and ESG Databook of Sai Life Sciences Limited for the FY 2025-26

    Others
    Reg. 34 (1) Annual Report.

    Integrated Annual Report of Sai Life Sciences Limited for the FY 2025-26

    AGM/EGMPrice-sensitive
    Notice Of 27Th Annual General Meeting (AGM) Of The Company

    Notice of 27th Annual General Meeting (AGM) of the Company

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication relating to 27th AGM (Pre-dispatch Advt.)

    Filed with BSE (scrip 544306); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 6 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Sai Life Sciences: common questions

    Answered from the figures on this page.

    Sai Life Sciences last traded at ₹1,788.10 (NSE, as of 18 Nov 2026). The last session moved it up 2.09%.

    Sai Life Sciences is valued at about ₹37,992 crore (NSE, as of 18 Nov 2026).

    Sai Life Sciences trades at a price-to-earnings ratio of 101.71 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Sai Life Sciences has traded between ₹783.85 and ₹1,954.80 over the past 52 weeks, to 18 Nov 2026. It is currently 86% of the way up that range.

    Sai Life Sciences (SAILIFE) is classified under Pharma on this site's screener.